Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut bugs linked to transplant complication risk

NCT ID NCT05186857

Knowledge-focused Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how changes in gut bacteria and their byproducts after a stem cell transplant might influence the development of graft-versus-host disease (GVHD), a serious complication. Researchers will collect stool and blood samples from 88 transplant recipients and their donors at several time points. By analyzing these samples, they hope to find patterns that predict GVHD and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict and prevent graft-versus-host disease by monitoring gut health, leading to better survival after transplant.
What could go wrong
This is an observational study, not a treatment trial. It may not find a clear link, and results may not lead to immediate changes in patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

88 people

The number who actually took part.

Started

Jan 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients receiving an allotransplant and family donors of the included patients.

Ages

1 year to 100 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patients Patients receiving an allotransplant at participating hospitals during the study period before initiating conditioning period. Inclusion Criteria: * Patients of any age who will receive allogeneic hematopoietic transplantation of any modality with any diagnosis. * Agreement of the patient to participate by signing the informed consent or his/her legal representatives/assent (if applicable). Exclusion Criteria \- Allotransplant recipients in stages after the initial pre-conditioning. Donors Family donors from patients included in the study: Inclusion criteria: * Agreement of the donor to participate by signing the informed consent or his/her legal representatives/assent (if applicable). * Donor relatives with any degree of identity in the Human Leukocyte Antigens (HLA). Exclusion Criteria: * Unrelated donors * Transplants from umbilical cord blood source.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Graft versus host disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Graft versus host disease

Contacts and locations

Locations

  • Hospital Clínico de Salamanca

    Salamanca, Salamanca, Spain

  • Hospital Clínico de Valencia

    Valencia, Valencia, Spain

  • Hospital La Paz, Madrid

    Madrid, Madrid, Spain

  • Hospital Marqués de Valdecillas, Santander

    Santander, Cantabria, Spain

  • Hospital Regional Universitario de Málaga

    Málaga, Málaga, Spain

  • Hospital Universitario Reina Sofía

    Córdoba, Córdoba, Spain

  • Hospital Universitario Virgen del Rocío, Sevilla

    Seville, Seville, Spain

  • Hospital Virgen de las Nieves de Granada

    Granada, Granada, Spain

  • Hospital del Niño Jesús, Madrid

    Madrid, Madrid, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.